Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 EP427 | DOI: 10.1530/endoabs.81.EP427

1Busan Bumin Hospital, Division of Endocrinology and Metabolism, Department of Internal Medicine, Busan, Rep. of South Korea; 2Ajou University School of Medicine, Department of Endocrinology and Metabolism, Suwon, Rep. of South Korea; 3Seoul Medical Center, Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul, Rep. of South Korea; 4Ajou University School of Medicine, Department of Physiology, Suwon, Rep. of South Korea

Iron also plays an important role in many physiological processes, including redox balance, inflammation, and metabolism. It is reported perturbation of iron (Fe) homeostasis has also been associated with metabolic diseases. Iron reduction, with iron chelator, has preventive effects in cardiovascular remodeling and obesity. On the other hand, deferoxamine (DFO) increases hypoxia and collagen production in the kidney. Thus, the effects of DFO on metabolic disease remains controversial. As a result, we investigated the effects of DFO on obesity, inflammation, insulin resistance, and diabetes in db/db mice models with type 2 diabetes. An in vivo study was performed on 7-week-old db/db mice. Mice were treated with DFO (100 mg/kg) or placebo every other day for 16 weeks. After treatment, an intraperitoneal glucose tolerance test and immunohistological examinations were performed. Fasting insulin and serum lipid levels were measured at the end of the study. Also, genes involved in inflammation and lipid metabolism were analyzed by real-time PCR. The DFO treated mice showed improved obesity, insulin resistance, and decreased levels of plasma inflammatory cytokines, total cholesterol, free fatty acid, and triglycerides. Fasting glucose in mice was also reduced by DFO treatment. Immunoblot analysis shows transferrin receptor 1 (TfR1) levels were increased in skeletal muscles of db/db mice models with type 2 diabetes. But DFO treatment decreased transferrin receptor 1 (TfR1) levels in skeletal muscles. DFO treatment also attenuated inflammatory cytokines and lipid deposition in the liver. Therefore, we consider the fine tuning of iron levels through DFO treatment as highly suggestive for preventing and/or treating insulin resistance and diabetes.

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.